NMD Pharma ApS Annual Report for 1 January - 31 December 2017
Company Presentation
NMD Pharma A/S | LinkedIn
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Management — NMD Pharma
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Big deal: NMD flexes series A muscles - Global University Venturing
NMD Pharma
NMD Pharma
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
Management — NMD Pharma
Event: Aarhus - Brew Your Own: Meet the founders - Biopeople
NMD Pharma - Inkef capital
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
Nmd Pharma A/S, Aarhus N | firma | krak.dk
NMD Pharma company information, funding & investors | Dealroom.co
NMD bags €38M to run orphan neuromuscular disease trials | FierceBiotech
Company Presentation
Management — NMD Pharma
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma — NMD Pharma
NMD Pharma to advance neuromuscular disorder therapies with €38m Series A round
Management — NMD Pharma
